TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33205280

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rescue medication
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Surgical parameters (duration, difficulty)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CYP2C8 and C9 SNPs
Number of subjects: 200
Study: 33205510

Group type: EXPERIMENTAL
Intervention: Periodontal treatment with mechanical debridement plus systemic amoxicillin/metronidazole for 7 days
Number of subjects: 66
Study: 33206198

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injection alongside physical therapies
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injection
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Therapy following botulinum toxin-A injection
Number of subjects: 953

Group type: COMPARATOR
Intervention: Commercially-available botulinum toxin-A agents
Number of subjects: 953
Study: 33206229

Group type: EXPERIMENTAL
Intervention: Haemoadsorption
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no haemoadsorption)
Number of subjects: 76
Study: 33206392

Group type: COMPARATOR
Intervention: Intravitreal dexamethasone implant 0.7mg
Number of subjects: 4348
Study: 33206624

Group type: EXPERIMENTAL
Intervention: Discover Learning Intervention (3-arm randomized controlled trial with incremental intervention components)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Discover Learning content (child-friendly videos, facilitated discussions, parent-child workbook)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: After-school, technology-driven, experiential learning sessions
Number of subjects: 579
Study: 33206936

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RNA expression profiling
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Integrated analysis of WGS and RNA expression data
Number of subjects: 17
Study: 33207004

Group type: EXPERIMENTAL
Intervention: Pessary
Number of subjects: 478

Group type: COMPARATOR
Intervention: Pessary plus PFMT
Number of subjects: 478
Study: 33207078

Group type: EXPERIMENTAL
Intervention: Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Enthesitis score
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Metrology Index
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 644
Study: 33207247

Group type: EXPERIMENTAL
Intervention: GDF-15 neutralization with monoclonal antibody mAB1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy agents with high clinical emetic score
Number of subjects: 0

Group type: COMPARATOR
Intervention: GDF-15 knockout mice
Number of subjects: 0
Study: 33207939

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no oxytocin)
Number of subjects: 28
Study: 33208055

Group type: EXPERIMENTAL
Intervention: BRASS intervention
Number of subjects: 0
Study: 33208090

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Number of comorbidities
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Quality of life physical component summary
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Quality of life mental component summary
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Higher-income
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Recent hospitalization
Number of subjects: 182
Study: 33208134

Group type: EXPERIMENTAL
Intervention: High physical work demands and leg pain intensity ≥7 (scale 0-10)
Number of subjects: 12879

Group type: EXPERIMENTAL
Intervention: Combination of high physical work demands and high leg pain intensity
Number of subjects: 12879
Study: 33208158

Group type: EXPERIMENTAL
Intervention: Peptide mimetic of ADAM22 ligand LGI1 (LGI1MIM)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: ADAM22
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Global transcriptomic analysis
Number of subjects: 843
Study: 33208301

Group type: EXPERIMENTAL
Intervention: Active Brains-Fitbit (AB-F)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 21
Study: 33208326

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment consisting of sofosbuvir and daclatasvir for 12 weeks, with ribavirin added in cases of cirrhosis.
Number of subjects: 1050
Study: 33208914

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT) for consolidation in s/tAML patients
Number of subjects: 644

Group type: COMPARATOR
Intervention: Allogeneic stem cell transplantation (HSCT) for consolidation in de novo AML patients
Number of subjects: 644
Study: 33209056

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB) with 25 mL bupivacaine 0.25%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 25 mL bupivacaine 0.25%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Morphine group
Number of subjects: 75
Study: 33209058

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Accelerated Radiotherapy (MARA) with concomitant boost (CB)
Number of subjects: 321
Study: 33209428

Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Subcarinal lymph node dissection
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Postoperative acid reflux
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Duration of anesthesia (over 153 minutes)
Number of subjects: 135
Study: 33209616

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using an ultrathin cryoprobe (1.1 mm diameter)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using an ultrathin cryoprobe
Number of subjects: 20
Study: 33209621

Group type: EXPERIMENTAL
Intervention: ctDNA methylation classifier
Number of subjects: 10560

Group type: COMPARATOR
Intervention: Physician cancer probability estimates
Number of subjects: 10560

Group type: COMPARATOR
Intervention: Validated lung nodule risk models (Mayo Clinic and Veteran's Affairs models)
Number of subjects: 10560
Study: 33209626

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with immunotherapy (pembrolizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment strategies
Number of subjects: 0
Study: 33209881

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/day)
Number of subjects: 30
Study: 33210209

Group type: EXPERIMENTAL
Intervention: Diagnostic pathway including clinical risk stratification (Alvarado score), routine ultrasonography, gynecology consult for females, and selected CT after clinical reassessment.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Diagnostic pathway
Number of subjects: 183
Study: 33210217

Group type: EXPERIMENTAL
Intervention: Family-administered delirium detection tools
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Family participation in delirium detection
Number of subjects: 18
Study: 33210276

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 62
Study: 33210333

Group type: EXPERIMENTAL
Intervention: Vedolizumab Q8W dosing
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 311
Study: 33210445

Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGI-S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISI
Number of subjects: 0
Study: 33210466

Group type: EXPERIMENTAL
Intervention: Bone scan (BS) preoperatively
Number of subjects: 691
Study: 33210570

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study: 33210751

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 4186
Study: 33211022

Group type: EXPERIMENTAL
Intervention: MDA with IVM plus dihydroartemisinin-piperaquine (DP) in intervention villages
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard malaria interventions according to the Gambian National Malaria Control Program in control villages
Number of subjects: 32
Study: 33211315

Group type: EXPERIMENTAL
Intervention: Pimasertib (28-255 mg/day)
Number of subjects: 93
Study: 33211344

Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 26
Study: 33211762

Group type: EXPERIMENTAL
Intervention: Biliary microbiota characterization using 16S rRNA gene sequencing and shotgun DNA sequencing.
Number of subjects: 0
Study: 33211842

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (ADCT-402) at doses ranging from 15 to 200 µg/kg, with a recommended dose of 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks.
Number of subjects: 183
Study: 33211907

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtA)
Number of subjects: 313
Study: 33212030

Group type: EXPERIMENTAL
Intervention: Dengue IgG indirect ELISA
Number of subjects: 2996

Group type: COMPARATOR
Intervention: Focus Reduction Neutralisation Test (FRNT)
Number of subjects: 2996
Study: 33212251

Group type: COMPARATOR
Intervention: Shipping vs local processing
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Temperature (4 °C vs ambient temperature)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Collection tube type (heparin vs Cell Save (CS) preservation tubes)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Treatment effect (pre- vs post-chemotherapy)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Transit time
Number of subjects: 1515
Study: 33212487

Group type: EXPERIMENTAL
Intervention: Surgical repair via a modified Ravitch procedure
Number of subjects: 19
Study: 33212917

Group type: EXPERIMENTAL
Intervention: DEM-TACE using LifePearl
Number of subjects: 97
Study: 33213012

Group type: EXPERIMENTAL
Intervention: Pitavastatin pretreatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33213035

Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethylxanthine (TMX)
Number of subjects: 93
Study: 33213729

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 8395
Study: 33213734

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study: 33213747

Group type: EXPERIMENTAL
Intervention: Evolut R/Evolut PRO
Number of subjects: 411

Group type: COMPARATOR
Intervention: SAPIEN 3
Number of subjects: 411
Study: 33213814

Group type: EXPERIMENTAL
Intervention: S-ICD System
Number of subjects: 1637
Study: 33213813

Group type: EXPERIMENTAL
Intervention: Extravascular ICD system
Number of subjects: 21
Study: 33213832

Group type: EXPERIMENTAL
Intervention: Digital Clinical Checklist (DCC)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Paper Checklist (Control)
Number of subjects: 197
Study: 33213826

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 8395
Study: 33213866

Group type: EXPERIMENTAL
Intervention: Postoperative Cognitive Dysfunction (POCD)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Serum S100B levels
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Duration of anesthesia
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Duration of Trendelenburg position
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Composite Z score in tests
Number of subjects: 82
Study: 33214207

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Standardised echocardiographic measurements
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Surveillance for aortic events
Number of subjects: 230
Study: 33214209

Group type: EXPERIMENTAL
Intervention: Inhaled TD139 (0.3-10 mg, once daily for 14 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled TD139 (0.15-50 mg, single doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33214489

Group type: EXPERIMENTAL
Intervention: Endotype iA (n = 47)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endotype iB (n = 44)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endotype iC (n = 11)
Number of subjects: 102
Study: 33214615

Group type: EXPERIMENTAL
Intervention: Preemptive interferon-α (IFN-α) treatment
Number of subjects: 68
Study: 33214879

Group type: EXPERIMENTAL
Intervention: Telemedicine solution for the post-anesthesia care unit
Number of subjects: 0
Study: 33215206

Group type: EXPERIMENTAL
Intervention: Intraoperative anatomical markings and surgical specimens analysis
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Bowel resection length and central radicality
Number of subjects: 4000
Study: 33215294

Group type: EXPERIMENTAL
Intervention: Therapeutic Patient Education (TPE) programme
Number of subjects: 0
Study: 33215544

Group type: EXPERIMENTAL
Intervention: Novel free-circulating and extracellular vesicle-derived miRNAs
Number of subjects: 0
Study: 33215602

Group type: EXPERIMENTAL
Intervention: Temporal artery thermometer (TAT)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Rectal thermometer (REC)
Number of subjects: 381
Study: 33215698

Group type: COMPARATOR
Intervention: Medical/surgical masks
Number of subjects: 61372

Group type: COMPARATOR
Intervention: N95/P2 respirators
Number of subjects: 61372

Group type: COMPARATOR
Intervention: Hand hygiene
Number of subjects: 61372

Group type: COMPARATOR
Intervention: Quarantine/physical distancing
Number of subjects: 61372
Study: 33216188

Group type: EXPERIMENTAL
Intervention: Double-bundle anterior cruciate ligament reconstruction (DBR)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Single-bundle anterior cruciate ligament reconstruction (SBR)
Number of subjects: 103
Study: 33216238

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) 15 mcg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral oxycodone extended release 10 mg twice daily and oral oxycodone immediate-release 5 mg up to four times daily on demand (Oxy group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral oxycodone (Oxy group)
Number of subjects: 72
Study: 33216280

Group type: EXPERIMENTAL
Intervention: PAX4 R192H
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PAX4 R192S
Number of subjects: 80
Study: 33216287

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) treatment
Number of subjects: 285
Study: 33216356

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab (nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every 3 weeks for 4 doses, followed by 480 mg of nivolumab intravenously every 4 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 55
Study: 33216772

Group type: EXPERIMENTAL
Intervention: Serum apolipoprotein-A1 at 1.25 g/L cutoff
Number of subjects: 232949

Group type: EXPERIMENTAL
Intervention: Serum apolipoprotein-A1
Number of subjects: 232949
Study: 33216879

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril
Number of subjects: 11506

Group type: COMPARATOR
Intervention: HCTZ/benazepril
Number of subjects: 11506
Study: 33216887

Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs) against BKPyV
Number of subjects: 41
Study: 33217027

Group type: COMPARATOR
Intervention: CSL112 (6 g dosing)
Number of subjects: 0
Study: 33217193

Group type: EXPERIMENTAL
Intervention: Any treatment for recurrence
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Sorafenib therapy
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Surgery/trans-arterial chemoembolization (TACE)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Early recurrence
Number of subjects: 1085
Study: 33217357

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody treatment (mAB114 or REGN-EB3)
Number of subjects: 2
Study: 33217414

Group type: EXPERIMENTAL
Intervention: Women undergoing pulmonary resections for lung cancer
Number of subjects: 6356
Study: 33217419

Group type: EXPERIMENTAL
Intervention: Incremental cardiopulmonary exercise testing (CPET) at the ventilatory threshold (Tvent)
Number of subjects: 96
Study: 33218740

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa treatment
Number of subjects: 560
Study: 33218965

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 490

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Treatment-free interval
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Ongoing treatment (≥1 year)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Grade 3/4 toxicity
Number of subjects: 490
Study: 33219014

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) at dose level 1 (DL 1 = 10) combined with neoadjuvant chemotherapy (NAC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) at dose level 2 (DL 2) combined with neoadjuvant chemotherapy (NAC)
Number of subjects: 9
Study: 33219092

Group type: EXPERIMENTAL
Intervention: Avelumab (programmed death ligand 1 inhibitor)
Number of subjects: 1783
Study: 33219118

Group type: EXPERIMENTAL
Intervention: Spatial frequency domain imaging (SFDI)
Number of subjects: 35
Study: 33219145

Group type: EXPERIMENTAL
Intervention: Skeletal muscle MRI and proton magnetic resonance spectroscopy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Skeletal muscle MRI
Number of subjects: 31
Study: 33219433

Group type: EXPERIMENTAL
Intervention: Incremental exhaustive bout of exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Type 1 diabetes participants
Number of subjects: 22
Study: 33219460

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 256
Study: 33219463

Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion entropy (MPE)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Stress perfusion defect (SSS≥4)
Number of subjects: 166
Study: 33219935

Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 3363
Study: 33219986

Group type: EXPERIMENTAL
Intervention: Low-nickel diet for 8 weeks
Number of subjects: 20
Study: 33220319

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 373
Study: 33220762

Group type: COMPARATOR
Intervention: High adherence to the Mediterranean lifestyle index (>14 points)
Number of subjects: 20494

Group type: COMPARATOR
Intervention: Each additional point in Mediterranean lifestyle index
Number of subjects: 20494

Group type: COMPARATOR
Intervention: High adherence to Mediterranean lifestyle index among participants aged ≥50 years
Number of subjects: 20494

Group type: COMPARATOR
Intervention: High adherence to Mediterranean lifestyle index among participants aged <50 years
Number of subjects: 20494
Study: 33221175

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.7 mg/kg administered intravenously every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Number of subjects: 28
Study: 33221216

Group type: EXPERIMENTAL
Intervention: High Calcified Plaque Volume (CPV)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: High Percent Calcified Plaque Volume (PCPV)
Number of subjects: 925
Study: 33221224

Group type: EXPERIMENTAL
Intervention: SPECT/CT imaging
Number of subjects: 25
Study: 33221242

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) with tagging
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nondiabetic age-matched controls
Number of subjects: 79
Study: 33221715

Group type: EXPERIMENTAL
Intervention: Bifrontal transcranial direct current stimulation (tDCS) applied using a 2 mA current for 20 min, twice daily, for 5 consecutive weekdays.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bifrontal transcranial direct current stimulation (tDCS)
Number of subjects: 80
Study: 33221907

Group type: EXPERIMENTAL
Intervention: Familial chylomicronemia syndrome (FCS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Multifactorial chylomicronemia syndrome (MCS)
Number of subjects: 29
Study: 33221921

Group type: EXPERIMENTAL
Intervention: 11C-MET PET-CT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clinical assessments and labial salivary gland biopsies
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 11C-MET uptake in lacrimal gland
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 18F-FDG uptake in parotid gland
Number of subjects: 12
Study: 33222307

Group type: EXPERIMENTAL
Intervention: Asthma-specific upper-airway microbiome composition (decreased ratio of Patescibacteria/Actinobacteria)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Frequent sweet consumption (≥ 7/week)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Reduced biodiversity
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Presence of Staphylococcus strains in the nasopharynx
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lower expression of beta-defensin 2, IL-5, and IL-13 in the nasal mucosa
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Frequent antibiotic use
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Higher nasal expression of IL-17 and T1R3 (sweet taste receptor)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Reduced sweet taste perception
Number of subjects: 133
Study: 33222379

Group type: EXPERIMENTAL
Intervention: Carbapenem monotherapy (primarily meropenem)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: BLBLI monotherapy (mostly piperacillin-tazobactam)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Any active therapy (including BLBLI and carbapenem)
Number of subjects: 306
Study: 33222617

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 93